Normal organ standard uptake values in carbon-11 acetate PET imaging

Nuclear Medicine Communications

Volumn 30, Issue 6, 2009, Pages 462-465

  Song, Won S ^a   Nielson, Brett R ^a   Banks, Kevin P ^a   Bradley, Yong C ^a  

^a BROOKE ARMY MEDICAL CENTER   (United States)

Author keywords

1111C acetate; Biodistribution; Normal; PET; Standard uptake value

Indexed keywords

ACETIC ACID C 11;

ADULT; AGED; ARTICLE; ASTROCYTOMA; CARCINOID; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC IMAGING; FEMALE; GLIOBLASTOMA; HUMAN; LIVER; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MUCINOUS CARCINOMA; MUCOSA ASSOCIATED LYMPHOID TISSUE LYMPHOMA; PANCREAS; PHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY; PROSTATE CANCER; SALIVARY GLAND; SENSITIVITY AND SPECIFICITY; SPLEEN;

ACETATES; ADULT; AGED; AGED, 80 AND OVER; CARBON RADIOISOTOPES; CARCINOMA, HEPATOCELLULAR; DIFFUSION; FEMALE; HUMANS; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; REFERENCE VALUES; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, X-RAY COMPUTED;

EID: 67649643579     PISSN: 01433636     EISSN: None     Source Type: Journal    
DOI: 10.1097/MNM.0b013e32832aa7ce     Document Type: Article

References (13)

1. Wahl RL. Clinical oncology update: the emerging role of positron emission tomography: parts I and II. In: Devita VTJr, Hellman S, Rosenberg SA, editors. Cancer: principles and practice of oncology. Philadelphia, Pennsylvania: Lippincott-Raven; 1997. pp. 1-24.
2. Kostakoglu L, Agress H Jr, Goldsmith SJ. Clinical role of FDG PET in evaluation of cancer patients. Radiographics 2003; 23:315-340.
3. 11C-acetate. Eur J Nucl Med Mol Imaging 2006; 33:420-427.
4. 11 C-acetate PET imaging in hepatocellular carcinoma and other liver masses. J Nucl Med 2003; 44:213-221.
5. Kato T, Tsukamoto E, Kuge Y, Takei T, Shiga T, Shinohara N, et al. Accumulation of C-acetate in normal prostate and benign prostatic hyperplasia: comparison with prostate cancer. Eur J Nucl Med Mol Imaging 2002; 29:1492-1495.
6. Dimitrakopoulou-Strauss A, Strauss LG. PET imaging of prostate cancer with C-acetate. J Nucl Med 2003; 44:556-558.
7. Sandblom G, Sorensen J, Lundin N, Haggman M, Malmstrom PL). Positron emission tomography with C11 -acetate for tumor detection and localization in patients with prostate-specific antigen relapse after radical prostatectomy. Urology 2006; 67:996-1000.
8. Lawrentsohuk N, Davis ID, Bolton DM, Scott AM. Positron emission tomography (PET), immuno-PET and radioimmunotherapy in renal cell carcinoma: a developing diagnostic and therapeutic relationship. BJU Int 2006; 97:916-922.
9. Seltzer MA, Jahan SA, Sparks R, Stout DB, Satyamurthy N, Dahlbom M, er al. Radiation dose estimates in humans for C-acetate whole-body PET. J Nucl Med 2004; 45:1233-1236.
10. Schiepers C, Hoh CK, Nuyts J, Seltzer M, Wu C, Huang SC, Dahlbom M. C-acetate kinetics of prostate cancer. J Nucl Med 2008; 49:206-215.
11. 99mTc-MIBI SPECT. Eur J Nucl Med Mol Imaging 2004; 31:13-21.
12. 11 C-acetate in the early evaluation of prostate cancer recurrence. Eur J Nucl Med Mol Imaging 2007; 34:185-196.
13. 11 C-acetate positron emission tomography imaging for lung adenocarcinoma 1 -3 cm in size with ground-glass opacity images on computed tomography. Ann Thorac Surg 2005; 80:2020-2025.++